Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

Gordon Research Conference awards to Haugsten and Zakrzewska

 
Haugsten (left) and Zakrzewska
Haugsten (left) and Zakrzewska

Ellen Margrethe Haugsten from Antoni Wiedlocha’s group at the Department of Biochemistry was awarded a prize for her talk - entitled "Clathrin – and dynamin-independent endocytosis of FGFR3 – implication for signaling", at the "Gordon Research Conference: Fibroblast Growth Factors in Development & Disease", held May 13-18, 2012 at Les Diablerets, Switzerland.
Malgorzata Zakrzewska received the price for a poster on "ERK-mediated phosphorylation of FGF receptor 1 on Ser777 confers negative feedback on FGF signaling", with Ellen M. Haugsten, Beata Nadratowska-Weselowska, Angela Oppelt, Yixin Jin, Jacek Otlewski, Jørgen Wesche and Antoni Wiedlocha,

 
 

Institute Seminar - Wednesday May 23rd

Giske Ursin

 

The institute seminar on Wednesday May 23rd will be held by Giske Ursin, Director of the Cancer Registry of Norway.

Title of her talk: How can the Norwegian cancer registry improve our biological understanding of cancer and cancer care?

Time and place: 12.00, Auditorium, new research building, Montebello.

 
 

Untangling the development of breast cancer

Researchers announce the first comprehensive genome studies of the evolution of 21 breast cancers

 
Langerød (left) and Børresen-Dale
Langerød (left) and Børresen-Dale

In two back-to-back reports published online on 17 May in Cell (journal impact factor 32.4) , researchers have sequenced the genomes of 21 breast cancers and analysed the mutations that emerged during the tumours‟ development.
Led by researchers from the Wellcome Trust Sanger Institute, the team created a catalogue of all the mutations in the genomes of the 21 cancer genomes and identified the mutational processes that lead to breast cancer. They found that these mutations accumulate in breast cells over many years, initially rather slowly, but picking up more and more momentum as the genetic damage builds up.

Anita Langerød and Anne-Lise Børresen-Dale (photo) from the Department of Genetics at the Institute for Cancer Research have made strong contributions to this work.

 
 

Understanding breast cancer

Landscape of cancer genes and mutational processes in breast cancer

 

In a study recently published in Nature (journal impact factor 36.1), researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40.

The team - which includes Anita Langerød and Anne-Lise Børresen-Dale from the Department of Genetics at the Institute for Cancer Research - examined all the genes in the genomes of 100 cases of breast cancer. The mutated cancer-causing genes were different in different cancer samples, indicating that breast cancer is genetically very diverse. Understanding the consequences of this diversity will be important in progressing towards more rational treatment.